Skip to main content

Table 3 Pretreatment 14-3-3η positivity and association with disease state

From: Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

  DAS28-ESR categorya SDAI category CDAI category
Cutpoint ≥0.19 ng/ml ≥0.40 ng/ml ≥0.80 ng/ml ≥0.19 ng/ml ≥0.40 ng/ml ≥0.80 ng/ml ≥0.19 ng/ml ≥0.40 ng/ml ≥0.80 ng/ml
Pretreatment LR 10.6 16.3 25.2 3.7 9.7 16.3 6.2 8.8 14.0
p-value 0.0011 <0.0001 <0.0001 0.16 (ns) 0.0077 0.0003 0.045 0.012 0.0009
1 yr LR 10.1 5.1 2.6 2.2 1 1 2.2 1.1 0.8
p-value 0.0064 0.079 (ns) 0.27 (ns) 0.34 (ns) 0.61 (ns) 0.61 (ns) 0.34 (ns) 0.57 (ns) 0.69 (ns)
  1. Abbreviations: DAS28-ESR Disease Activity Score in 28 joints with erythrocyte sedimentation rate, SDAI Simple Disease Activity Index, CDAI Clinical Disease Activity Index, LR likelihood ratio, ns not significant
  2. aCalculated based on 145 patients for pretreatment and 146 for 1 yr